PIK3CA mutation is associated with increased local failure in lung stereotactic body radiation therapy (SBRT)
| Autor: | E. Gelb, T. Jonathan Yang, Andreas Rimner, David Barron, Abraham J. Wu, Weiji Shi, Ellen Yorke, Zhigang Zhang, Daphna Y. Gelblum, Natalie A. Lockney |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2017 |
| Předmět: |
0301 basic medicine
Oncology medicine.medical_specialty Pathology Radiation resistance GTV gross tumor volume R895-920 BED biologically effective dose AKT1 SBRT stereotactic body radiation therapy ITV internal target volume AKT protein kinase B Article Lesion 03 medical and health sciences Medical physics. Medical radiology. Nuclear medicine 0302 clinical medicine Internal medicine Radioresistance medicine Radiology Nuclear Medicine and imaging neoplasms CTV clinical target volume PI3K/AKT/mTOR pathway RC254-282 Univariate analysis Lung business.industry PIP2 phosphatidylinositol-4 5-biphosphate Neoplasms. Tumors. Oncology. Including cancer and carcinogens PIK3CA medicine.disease PIP3 phosphatidylinositol-3 4 5-triphosphate Primary tumor CT computed tomography 3. Good health PI3K phosphatidylinositol-3-kinases 030104 developmental biology medicine.anatomical_structure Lung stereotactic body radiation therapy (SBRT) 030220 oncology & carcinogenesis Mutation (genetic algorithm) medicine.symptom LF local failure Local failure business PTV planning target volume |
| Zdroj: | Clinical and Translational Radiation Oncology, Vol 7, Iss, Pp 91-93 (2017) Clinical and Translational Radiation Oncology |
| ISSN: | 2405-6308 |
| Popis: | Highlights • An examination of mutations in PIK3CA signaling pathways and radioresistance. • PIK3CA mutation was found to be associated with local failure after lung SBRT. • This is a small study and there is need for further validation. Objectives Hyperactivation of the phosphatidylinositol-3-kinase (PI3K) pathway has been associated with radioresistance. It is unclear whether such mutations confer suboptimal local control for patients who receive lung stereotactic body radiation therapy (SBRT). Our objective was to examine whether mutations in the EGFR/AKT/PIK3CA signaling pathway are associated with local failure (LF) after lung SBRT. Methods We retrospectively reviewed 166 patients who underwent SBRT to primary or metastatic lung lesions from 2007 to 2015 for whom genetic testing data was available for EGFR, AKT, and PIK3CA genes. Association between clinical factors, including molecular mutation status, and LF was evaluated. Results Six patients (4%) had PIK3CA mutation, 36 patients (22%) had EGFR mutation, and one patient (0.6%) had AKT1 mutation. Median lesion size was 2.0 cm (range, 0.6–5.6 cm); median dose was 48 Gy in 4 fractions (range, 30–70 Gy in 3–10 fractions). Median follow-up for survivors was 27.3 months (range, 3.8–66.7 months). LF occurred in 16 patients (10%). On univariate analysis, PIK3CA mutation was associated with LF (HR 10.44 [95% CI 2.16–50.46], p = .003), while tumor histology, tumor size, primary tumor site, BED and EGFR mutation were not. At one year, probability of LF in lesions with PIK3CA mutation was 20.0% vs. 2.9% in lesions without mutation (p |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|